EuroBiotech: More Articles of Note

Newspapers

> Millendo Therapeutics bought France’s Alizé Pharma. Statement 

> Summit Therapeutics offloaded the Latin American rights to its Clostridium difficile infection drug. Statement

> The EMA’s drug review committee recommended the approval of TiGenix and Takeda’s allogeneic stem cell therapy. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Active Biotech warned it must sell a property or otherwise raise money before the end of February, otherwise it “will not have funding for the coming twelve-month period.” Statement

> The FDA awarded qualified infectious disease product status to Basilea Pharmaceutica’s ceftobiprole. Release 

> Ablynx posted data from a Japanese ethno-bridging study of caplacizumab. Statement 

> BiomX bought RondinX to expand its microbiome discovery and development capabilities. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.